FDA Approves First-in-Class Drug for Follicular Lymphoma
The first-in-class bispecific antibody mosunetuzumab-axgb (Lunsumio) has been granted an accelerated approval for use in relapsed or refractory follicular lymphoma.
FDA Approvals
source https://www.medscape.com/viewarticle/986083?src=rss
FDA Approvals
source https://www.medscape.com/viewarticle/986083?src=rss
Comments
Post a Comment